ArticleRadiology and oncology2012
Long term outcome after combined modality treatment for anal cancer.
Article in Radiology and oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- A systematic review on the role of interventional radiotherapy for treatment of anal squamous cell cancer: multimodal and multidisciplinary therapeutic approach.La Radiologia medica · 2024Pooled it
- Prognostic impact of anal cancer morphology on survival and local recurrence: A 20-year regional cohort study.Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland · 2026Article
- Very Late-Onset Serious Chronic Adverse Effects After Radical Chemoradiotherapy for Anal Canal Cancer.Journal of clinical medicine · 2025Article
- Photobiomodulation as a treatment for dermatitis caused by chemoradiotherapy for squamous cell anal carcinoma: case report and literature review.Radiation oncology (London, England) · 2022Review
- Long-term Oncologic Outcome and Its Relevant Factors in Anal Cancer in Korea: A Nationwide Data Analysis.Annals of coloproctology · 2020Article
- Chemoradiotherapy for anal cancer: are we as good as we think?Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2019Review
- Effects of social support and self-efficacy on the psychosocial adjustment of Korean ostomy patients.International wound journal · 2019Article
- Squamous-cell carcinoma of the anus: progress in radiotherapy treatment.Nature reviews. Clinical oncology · 2016Review
- Uncertainty Abounds in the World of Anal Dysplasia Screening.Sexually transmitted diseases · 2016Article
- The impact of anaemia on treatment outcome in patients with squamous cell carcinoma of anal canal and anal margin.Radiology and oncology · 2016Article
- Cancer incidence and mortality in the Greater Poland Region-Analysis of the year 2010 and future trends.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2014Review
- HDR brachytherapy for anal cancer.Journal of gastrointestinal oncology · 2014Review
- Individual radiosensitivity in a breast cancer collective is changed with the patients' age.Radiology and oncology · 2014Article
- Characteristics and survival of korean anal cancer from the Korea central cancer registry data.Annals of coloproctology · 2013Article
- Anal cancer: are we making progress?Current oncology reports · 2013Review
- Is rectal MRI beneficial for determining the location of rectal cancer with respect to the peritoneal reflection?Radiology and oncology · 2012Article
- The prescription of oral anticancer drugs: Another perspective.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of the retrospective study was to evaluate the effectiveness and toxicity of radiochemotherapy in patients with squamous cell carcinoma of the anal canal treated at a single institution. PATIENTS AND
methodsBetween 1/2003 and 9/2010, 84 patients were treated with radical radiochemotherapy at the Institute of Oncology Ljubljana, Slovenia. The treatment consisted of 3-dimensional conformal external beam radiotherapy with concurrent chemotherapy (5-fluorouracil and mytomycin C), followed by brachytherapy or external beam boost. The toxicity of therapy and its effectiveness were assessed.
resultsThe treatment was completed according to the protocol in 79.8% of patients. The median follow-up time of 55 survivors was 53 months (range: 16-105 months). The 5-year locoregional control (LRC), disease-free survival (DFS), disease-specific survival (DSS), overall survival (OS) and colostomy-free survival (CFS) rates were 71%, 68%, 81%, 67% and 85%, respectively. No treatment-related mortality was observed. The most frequent acute side-effect of the treatment was radiodermatitis (grade 3-4 in 58.2% of patients). LENT-SOMA grade 3-4 late radiation side effects were observed in 15 (18%) patients. In patients with brachytherapy boost a trend of less late side effects was observed compared to patients with external beam boost (P=0.066). On multivariate analysis, complete clinical disease response was identified as an independent prognostic factor for LRC, DFS and DSS, the salvage surgery for LRC and DFS, whereas Hb below 120 g/l retained its independent prognostic value for OS.
conclusionsRadiochemotherapy provides an excellent disease control and the survival with preserving anal sphincter function in majority of patients. Surgical salvage with abdominoperineal resection for persistent or recurrent disease has curative potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.